November 2023. No UNTS volume number has yet been determined for this record. The Text(s) reproduced below, if attached, are the authentic texts of the agreement /action attachment as submitted for registration and publication to the Secretariat. For ease of reference they were sequentially paginated. Translations, if attached, are not final and are provided for information only. *Aucun numéro de volume n'a encore été attribué à ce dossier. Les textes disponibles qui sont reproduits ci-dessous sont les textes originaux de l'accord ou de l'action tels que soumis pour enregistrement. Par souci de clarté, leurs pages ont été numérotées. Les traductions qui accompagnent ces textes ne sont pas définitives et sont fournies uniquement à titre d'information.
November 2023. The RL Loan is an unsecured loan on normal commercial terms and constitutes a fully exempted connected transaction, namely financial assistance by a connected person to the Company, under the Listing Rules. Given the current stringent financial position of the Group, the Board considers it is in the best interest of the Company not to proceed with the Subscription (even if Jianlibao Asia agrees to allow the Company to scale down the Subscription) but enter into the Assignment Agreement such that the Company shall be discharged and released from the Rights and Obligations under the Subscription Agreement. With True Choice assuming the obligation to subscribe for Jianlibao Asia’s shares and the set-off of the RL Loan against Subscription Deposit, the Company is relieved from the burden of servicing the RL Loan which would otherwise be extremely difficult in view of the current financial strain of the Company. Further had the Parties not entered into the Assignment Agreement, the Subscription Deposit would have been forfeited under the provision of the Subscription Agreement. True Choice will subscribe for the Adjusted Subscription at the same valuation as the Company subscribed under the Subscription which was based on a valuation of RMB6 billion for 100% of Jianlibao. The Assignment Agreement is the result of friendly negotiation between the Parties on an arm’s length basis with a view to help relieve the Company from further financial burden arising from the default on the Subscription Agreement. The Directors (excluding the independent non-executive directors whose view will be expressed in the circular after considering the opinion of the IFA) believe that the terms of the Assignment Agreement are fair and reasonable, on normal commercial terms after arm’s length negotiations between the Parties and in the interests of the Company and the Shareholders as a whole.
November 2023. This is an unofficial translation from Finnish. In cases of dispute, the Finnish text is authoritative. 978-952-238-286-3 978-952-238-294-8 (pdf) Xxxxx Oy, 2022 1 SCOPE OF THE AGREEMENT 15 2 BINDING CHARACTER OF THE AGREEMENT AND DUTY OF COMPLIANCE 16 3 PEACE OBLIGATION 16
November 2023. Double Red Fosphenytoin sodium (Pro-Epanutin®) ICB Status epilepticus, seizures with head injury,etc. Not recommended for routine use NICE has not issued any guidance. BLACK Fostamatinib Tavlesse® ICB refractory chronic immune thrombocytopenia Not commissioned. No NHS prescribing in primary or secondary care TA759 – January 2022 Hospital Fostamatinib Tavlesse® ICB refractory chronic immune thrombocytopenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA835 – October 2022 Double Red Fostemsavir () NHSE HIV infection in combination with other antiretroviral drugs Not recommended for routine use NICE has not issued any guidance. Hospital FreeStyle Libre BGS device (sensors are "Advice"") (FreeStyle Libre) ICB Blood Glucose Monitoring in diabetes as per NHSE criteria March 2019 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE FreeStyle Libre BGS sensors (BGS device is "Red") (FreeStyle Libre) ICB Blood Glucose Monitoring in diabetes as per NHSE criteria March 2019 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script. NICE has not issued any guidance. Hospital Fremanezumab Ajovy® ICB preventing migraine Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA764 – February 2022 BLACK Fulvestrant (Faslodex®) NHSE Treatment of locally advanced or metastatic breast cancer - as per NICE TA 503 Not commissioned. No NHS prescribing in primary or secondary care TA503 - Jan 18 Hospital Fumaric acid ester (Fumaderm (unlicensed product)) ICB Severe psoriasis - specialist use only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Gabapentin (Neurontin®) ICB Neuropathic pain Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. AMB Galantamine (Reminyl®) ICB Mild to moderate Alzheimer's dementia - as per NICE TA 217 Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review TA217 - Mar 11 B...
November 2023. Final Report A report of outcomes for the funded Activity based on monitoring and data collection methods agreed with between the Parties as per Item E.4 28 July 2024 Financial Acquittal Report Audited Financial Acquittal Report covering the entire Activity period as per Item E.3 31 October 2024
November 2023. 0.00 December 2023... 0.00 January 2024.... 0.00 February 2024... 0.00 March 2024...... 0.00 April 2024...... 0.00 May 2024........ 0.00
November 2023. 0.00% XXXXXXXX X CLASS B CLASS PERCENTAGES CLASS B CLASS B CLASS B PAYMENT DATE MINIMUM SCHEDULED SUPPLEMENTAL OCCURRING IN PERCENTAGE PERCENTAGE PERCENTAGE ------------ ---------- ---------- ------------ July 2000............ 10.05% 10.01% 9.95% August 2000.......... 10.04% 10.00% 9.94% September 2000....... 10.03% 9.99% 9.93% October 2000......... 10.03% 9.99% 9.92% November 2000........ 10.02% 9.98% 9.92% December 2000........ 9.94% 9.90% 9.84% January 2001......... 9.94% 9.90% 9.84% February 2001........ 9.94% 9.90% 9.83% March 2001........... 9.94% 9.90% 9.83% April 2001........... 9.94% 9.90% 9.83% May 2001............. 9.94% 9.90% 9.82% June 2001............ 9.94% 9.90% 9.82% July 2001............ 9.94% 9.90% 9.82% August 2001.......... 9.94% 9.90% 9.81% September 2001....... 9.94% 9.91% 9.80% October 2001......... 9.95% 9.91% 9.80% November 2001........ 9.95% 9.91% 9.79% December 2001........ 9.95% 9.91% 9.78% January 2002......... 9.95% 9.91% 9.78% February 2002........ 9.95% 9.91% 9.77% March 2002........... 9.95% 9.91% 9.76% April 2002........... 9.95% 9.91% 9.75% May 2002............. 9.95% 9.91% 9.74% June 2002............ 9.95% 9.91% 9.73% July 2002............ 9.95% 9.91% 9.72% August 2002.......... 9.95% 9.91% 9.71% September 2002....... 9.95% 9.91% 9.70% October 2002......... 9.95% 9.91% 9.69% November 2002........ 9.95% 9.91% 9.67% December 2002........ 9.95% 9.91% 9.66% January 2003......... 9.95% 9.91% 9.65% February 2003........ 9.95% 9.91% 9.63% March 2003........... 9.95% 9.91% 9.62% April 2003........... 9.95% 9.91% 9.60% May 2003............. 9.95% 9.91% 9.59% June 2003............ 9.95% 9.90% 9.57% July 2003............ 9.95% 9.90% 9.55% August 2003.......... 9.95% 9.90% 9.53% September 2003....... 9.95% 9.90% 9.52% October 2003......... 9.95% 9.90% 9.50% November 2003........ 9.95% 9.90% 9.48% December 2003........ 9.95% 9.90% 9.46% January 2004......... 9.95% 9.90% 9.44% February 2004........ 9.95% 9.90% 9.42% March 2004........... 9.95% 9.90% 9.40% April 2004........... 9.95% 9.90% 9.38% May 2004............. 9.95% 9.90% 9.35% June 2004............ 9.95% 9.89% 9.33% July 2004............ 9.95% 9.89% 9.31% August 2004.......... 9.95% 9.89% 9.28% September 2004....... 9.95% 9.89% 9.26% October 2004......... 9.95% 9.89% 9.23% November 2004........ 9.95% 9.89% 9.21% December 2004........ 9.95% 9.88% 9.18% January 2005......... 9.95% 9.88% 9.16% CLASS B CLASS B CLASS B PAYMENT DATE MINIMUM SCHEDULED SUPPLEMENTAL OCCURRING IN PERCENT...
November 2023. A. Whereas the land subject to this Agreement (the “Agreement Area”) is within Hənʎəmdᶻi Məkola/Yorke Island Conservancy, and whereas Hənʎəmdᶻi Məkola/Yorke Island Conservancy is within the traditional territories of the K’omoks First Nation, We Wai Kai First Nation, Xxx Xxx Xxx First Nation & Xwemalhkwu First Nation whose relationship with the land continues to this day.
November 2023. Cancer Institute – Xxxxxx xxx Xxxxxxxxxxx hospital, I work for and amidst patients, researchers and clinicians. As a result, I use and interpret the legislation and legal theory of data protection in my daily work, and vice versa. The case studies in this thesis reflect daily practice in health care and secondary health research. My research strategy has consisted of four steps.17 First, I identified the field of re- search, i.e. data protection in health care and health research. Secondly, I collected sources. I collected documents on the letter of the law, publications and academic research carried out in previous studies. Thirdly, I analyzed the sources and, finally, I interpreted the sources. Often, the four steps of the research strategy took place paral- lel to each other, whilst I observed converging and diverging developments as regards both European and national law, and the viewpoints of legal scholars and practitioners in this field. I started this thesis at the xxxx of the COVID-19 pandemic when the urgent need for data sharing for health and research became all the more apparent.
November 2023. Double Red Fosphenytoin sodium (Pro-Epanutin®) ICB Status epilepticus, seizures with head injury,etc. Not recommended for routine use NICE has not issued any guidance. BLACK Fostamatinib Tavlesse® ICB refractory chronic immune thrombocytopenia Not commissioned. No NHS prescribing in primary or secondary care TA759 – January 2022 Hospital Fostamatinib Tavlesse® ICB refractory chronic immune thrombocytopenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA835 – October 2022 Double Red Fostemsavir () NHSE HIV infection in combination with other antiretroviral drugs Not recommended for routine use NICE has not issued any guidance. Hospital FreeStyle Libre BGS device (sensors are "Advice"") (FreeStyle Libre) ICB Blood Glucose Monitoring in diabetes as per NHSE criteria March 2019 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE FreeStyle Libre BGS sensors (BGS device is "Red") (FreeStyle Libre) ICB Blood Glucose Monitoring in diabetes as per NHSE criteria March 2019 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script. NICE has not issued any guidance.
